
Recursion Pharmaceuticals Stock
Automated drug discovery platform
Sign up today and learn more about Recursion Pharmaceuticals Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Recursion Pharmaceuticals Stock
Recursion Pharmaceuticals is an automated drug discovery platform. The company combines experimental biology, automation, and artificial intelligence in a parallel system that aims to efficiently identify treatments for any disease which can be modeled at the cellular level. The company uses computer vision to study images of how diseases affect healthy cells and claims to have put together the largest biological image set in the world, as it tracks almost half a million experiments a week.
Recursion Pharmaceuticals has broadened its platform to probe data from automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. While the company tries to make its own drugs for rare discoveries, it has also sought partnerships with major pharmaceutical companies like Sanofi and Takeda, on other rare diseases, hoping to tackle oncology and inflammation.
The company is headquartered in Salt Lake City, Utah and was founded by Blake Borgeson, Chris Gibson, and Dean Li in 2013.
Investors
AME Cloud Ventures
Lacework, Wish, Eat Just, Zymergen, Illumio, Recursion Pharmaceuticals, Freenome, Astranis, FiscalNote, Planet
CRV
DoorDash, Airtable, Bird, Fair, Cybereason, Twitter, Niantic, ClassPass, Recursion Pharmaceuticals, Freenome
Menlo Ventures
Uber, Chime, Machine Zone, Getaround, BitSight, Recursion Pharmaceuticals, Outreach, Benchling, Synthego, Abnormal Security
Mubadala Ventures
Obvious Ventures
Magic Leap, Devoted Health, Zymergen, Gusto, Recursion Pharmaceuticals, Mosaic, Virta Health, Diamond Foundry, Medium, Good Eggs
Scottish Mortgage Investment Trust
Two Sigma Ventures
Carbon Health, Recursion Pharmaceuticals, WHOOP, Socure, SecurityScorecard, D2iQ, Anki, Rethink Robotics, Enigma Technologies, Juicero
Funding History
September 2016 | $3.5M |
---|---|
September 2016 | $21.4M |
October 2017 | $60.1M |
February 2019 | $123M |
August 2020 | $308M |
Management
Co-Founder and Chief Executive Officer
Chris Gibson
Senior Vice President of Translational Discovery & Chief Evangelist
Ron Alfa
Vice President, Intellectual Property
Kevin Brown
Senior Vice President of Biology
Yolanda Chong
Vice President of Chemistry
Mike Genin
Vice President, Data Science
Imran Haque
Vice President of Finance
Nathan Hatfield
Chief Scientific Officer
Sharath Hegde
Vice President of Business Development & Corporate Initiatives
Matthew Kinn
Chief People Officer
Heather Kirkby
President and Chief Operating Officer
Tina Larson
Vice President, Core Operations
Adeline Low
Vice President of Engineering
Ben Mabey
Vice President of Project Management & Chief of Staff
Kristen Rushton
Chief Technology Officer & Chief Product Officer
Mason Victors
Press
Wall Streets Journal - Sep, 9 2020
Recursion Raises $239 Million Series D Round, Strikes Deal With BayerTechCrunch - Oct, 22 2019
LabGenius raises $10M to use AI for protein drug discoveryForbes - Sep, 27 2019
How To Spot A Synthetic Biology Unicornzdnet - Jul, 25 2019
The subtle art of really big data: Recursion Pharma maps the bodydeseretnews - Jul, 19 2019
Salt Lake's Recursion Pharma nails down $121 million in new fundingFinSMEs (blog) - Jun, 5 2018
Recursion Pharmaceuticals Raises $20.5M Credit Facility from Square 1 BankKCPW (blog) - May, 15 2018
100 Cures in 10 Years with Recursion PharmaceuticalsPR Newswire (press release) - May, 7 2018
Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious DiseaseCommercial Property Executive - Dec, 5 2017
Recursion to Open New HQ in SLCTechCrunch - Oct, 3 2017
Drug discovery startup Recursion raises $60 million in Series B from Data CollectiveEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase